Apparent migraines experienced by 19th century factory workers remain relevant to clinical medicine today. Those workers were employed in the

Atogepant, an oral, small-molecule, calcitonin gene–related peptide receptor antagonist that’s been in development as a preventive treatment for chronic migraine,